Evolent Health price target raised to $15 from $14 at UBS

UBS analyst Kevin Caliendo raised the firm’s price target on Evolent Health (EVH) to $15 from $14 and keeps a Buy rating on the shares. Evolent Health has better visibility into its future financials and growth algorithm than it did just five months ago following the repricing and recontracting of its major customer contracts, the analyst tells investors in a research note. The first quarter was a first step toward regaining credibility with shareholders and UBS sees the risk-reward as positive.